Tirzepatide 1 Month Results: What to Expect in Your First 4 Weeks

    By Trimi Medical Team8 min read

    The first month on tirzepatide (Mounjaro, Zepbound) sets the foundation for your weight loss journey. Like semaglutide, the starting dose of 2.5 mg is designed primarily for GI adjustment rather than maximum weight loss. However, tirzepatide's dual GIP/GLP-1 receptor action means many patients notice appetite changes earlier and more consistently than with semaglutide alone.

    Medical Disclaimer: This article is for informational purposes only. Individual results vary. Always follow your provider's treatment plan.

    Month 1 Weight Loss Data

    MetricAverageRange
    Weight loss (lbs)3-7 lbs0-12 lbs
    Body weight % lost1.5-3%0-5%
    Appetite reductionModerateMild to significant
    Dose2.5 mgStarting dose

    Tirzepatide vs. Semaglutide: Month 1 Comparison

    FactorTirzepatideSemaglutide
    Avg. month 1 loss3-7 lbs2-5 lbs
    Appetite suppression onsetOften within week 1Usually weeks 1-2
    Nausea incidence~15-25%~20-30%
    MechanismDual GIP + GLP-1GLP-1 only

    What to Expect Week by Week

    • Week 1: Many patients notice reduced appetite within 2-3 days. Mild nausea is possible. Weight may drop 1-2 lbs from water and reduced food intake.
    • Week 2: Appetite effects become more consistent. Eating patterns begin shifting. Nausea (if present) typically peaks and begins to subside.
    • Week 3: New eating patterns feel more natural. Side effects usually mild or absent. Steady weight loss underway.
    • Week 4: End of starting dose period. Most patients have adapted well and are ready for dose escalation to 5 mg.

    Maximizing First-Month Results

    • Prioritize protein (80-120g daily) from the start to protect muscle mass.
    • Stay hydrated: At least 64 oz water daily.
    • Eat slowly and stop when you feel satisfied, not stuffed.
    • Begin walking 20-30 minutes daily.
    • Track your food intake to build awareness.
    • Take progress photos and measurements, not just scale weight.

    Frequently Asked Questions

    How much weight do you lose in the first month on tirzepatide?

    Most patients lose 3-7 pounds at the 2.5 mg starting dose. Some see higher initial losses from water weight shifts and immediate appetite reduction. Zero loss is also within normal range.

    Is tirzepatide faster than semaglutide in the first month?

    Early data suggests slightly faster initial results with tirzepatide due to dual receptor action, but individual variation is significant and both medications follow gradual titration.

    What side effects are common in month 1 of tirzepatide?

    Nausea (~15-25%), diarrhea, decreased appetite, and mild injection site reactions. Most resolve within 2-3 weeks.

    Start your tirzepatide journey with expert support. Explore Trimi's treatment programs.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    Related Reading

    What does the published clinical evidence show for compounded tirzepatide?

    Peer-reviewed evidence: Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022). Trimi offers compounded tirzepatide starting at $125/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. — SURMOUNT-1, NEJM 2022
    In a 40-week head-to-head trial of patients with type 2 diabetes, tirzepatide 15 mg produced approximately 11.2 kg of body-weight reduction vs 5.7 kg on semaglutide 1 mg. — SURPASS-2, NEJM 2021
    Tirzepatide reduced the apnea-hypopnea index by approximately 27 to 30 events/hour at 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea, vs roughly 5 events/hour reduction on placebo. — SURMOUNT-OSA, NEJM 2024

    Key Takeaways

    • Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022)
    • In a 40-week head-to-head trial of patients with type 2 diabetes, tirzepatide 15 mg produced approximately 11.2 kg of body-weight reduction vs 5.7 kg on semaglutide 1 mg. (Source: SURPASS-2, NEJM 2021)
    • Tirzepatide reduced the apnea-hypopnea index by approximately 27 to 30 events/hour at 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea, vs roughly 5 events/hour reduction on placebo. (Source: SURMOUNT-OSA, NEJM 2024)
    • Tirzepatide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Zepbound and Mounjaro). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: October 26, 2025

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2206038
    2. Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2107519
    3. Wadden TA, Chao AM, Machineni S, et al. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-023-02597-w
    4. Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2023.24945
    5. Malhotra A, Grunstein RR, Fietze I, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2404881
    6. U.S. Food and Drug Administration (2024). Zepbound (tirzepatide) Prescribing Information. FDA.Read Study

    Was this article helpful?

    Keep Reading

    Essential preparation guide for tirzepatide. Learn eligibility, costs, side effects, timeline, and how to prepare for successful weight management.

    Clinician-reviewed guide to tirzepatide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded tirzepatide option compares.

    At 3 months on tirzepatide, average weight loss is 7-10% of body weight. See SURMOUNT trial data, dose-dependent results, and comparison with semaglutide at the same timepoint.

    Clinician-reviewed guide to tirzepatide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded tirzepatide option compares.

    Start your GLP-1 journey — from $99/mo

    Get Started